Advertisement

Adagrasib in KRAS G12C–Mutated NSCLC
Posted: 07/25/2022 | By: Chase Doyle

As reported in The New England Journal of Medicine, findings in a phase II cohort of the multicohort KRYSTAL-1 phase I/II study indicated that the KRAS G12C inhibitor adagrasib showed activity in previously treated patients with unresectable or metastatic NSCLC and a KRAS G12C mutation.

Question 1 of 5

In the phase I/II KRYSTAL-1 study, what percentage of patients with measurable KRAS G12C–mutated NSCLC at baseline had a confirmed objective response to the KRAS G12C inhibitor adagrasib?

Choose 1

A
22.9%
B
32.9%
C
42.9%
D
52.9%

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage